anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Osteoarthritis (OA) of the thumb carpometacarpal (CMC) joint is a common disorder that negatively impacts hand function. Denervation of the thumb CMC joint has emerged as a viable treatment option. However, the innervation pattern of the thumb CMC joint is controversial. Therefore, the objective of this study was to identify the articular branches supplying the thumb CMC joint and to document their relationship to anatomical landmarks to provide the foundation for image-guided diagnostic block and denervation procedures.
METHODS: In 10 formalin-embalmed upper limb specimens articular branches supplying the thumb CMC joint were dissected from their origin to termination. A frequency map documenting the number of articular branches was generated. The frequency map enabled visualization and comparison of the relative area of innervation of the thumb CMC joint by each articular branch.
RESULTS: The thumb CMC joint received innervation from six nerves. These were the deep branch of ulnar nerve (DBUN), dorsal articular nerve (DAN) of the first interosseus space, thenar branch of median nerve (TBMN), palmar cutaneous branch of median nerve (PCBMN), lateral antebrachial cutaneous nerve (LACN) and superficial branch of the radial nerve (SBRN) and/or their branches. Each nerve was found to innervate different aspects of the joint. The DBUN and DAN were found to innervate the posteromedial aspect of the thumb CMC joint, the TBMN and PCBMN anterior/anteromedial aspects, LACN posterolateral/lateral/anterior aspects and SBRN posterolateral/anterolateral aspects.
CONCLUSIONS: The thumb CMC joint was innervated by articular branches originating from the SBRN, DAN, LACN, PCBMN, TBMN and DBUN. The documented anatomical relationships provide the foundation to inform selective diagnostic block and denervation of the thumb CMC joint. Further investigations are needed to assess the clinical implications of the current study.
BACKGROUND: Observational studies have indicated a possible connection between Helicobacter pylori (H. pylori) infection and eosinophilic esophagitis (EoE), but their causal relationship has yet to be established. To investigate the causal associations between H. pylori infection and EoE, we performed a Mendelian randomization (MR) analysis.
METHODS: Firstly, we conducted both univariable and multivariable Mendelian randomization (MR) analyses. Furthermore, a two-step MR was carried out to ascertain the potential underlying pathways of these associations, particularly the involvement of inflammatory cytokines. We employed the inverse-variance weighted (IVW) method as the main analysis in our MR study. To enhance the credibility of the results, we also conducted several sensitivity analyses.
RESULTS: Our study demonstrated a noteworthy correlation between genetically predicted anti-H. pylori IgG antibody levels and a reduced risk of EoE (OR=0.325, 95% CI=0.165-0.643, P value=0.004, adj p value=0.009). No significant causal associations were detected between other H. pylori antibodies and EoE in our study. When it comes to multivariable MR analysis controlling for education attainment, household income, and deprivation individually, the independent causal impact of anti-H. pylori IgG on EoE persisted. Surprisingly, the two-step MR analysis indicated that inflammatory factors (IL-4, IL-5, IL-13, IL-17, and IFN-γ) did not appear to mediate the protective effect of H. pylori infection against EoE.
CONCLUSION: Findings suggested that among the range of H. pylori-related antibodies, anti-H. pylori IgG antibody is the sole causal factor associated with protection against EoE. Certain inflammatory factors may not be involved in mediating this association. These findings make a significant contribution to advancing our understanding of the pathogenesis of EoE and its evolving etiology.
PROBLEM TO BE SOLVED: To make it possible to maintain high white cell removability and to improve handling quality by providing the inside of the connecting tube on the downstream side of a white cell removing filter with a small-diameter part for flow velocity adjustment. SOLUTION: This white cell removing device is constituted by connecting a blood bag 7 and a recovering bag 7 to each other by intervening an introducing port 1, the white cell removing filter 2, a leading-out port 6, connecting pipes 3, 3', a meshed chamber 4 and a Robert clamp 5 therebetween. In such a case, the downstream side of the white cell removing filter 2 is provided with a small-diameter part A for flow velocity adjustment. The effective sectional area of this small-diameter part A for flow velocity adjustment is set at a range of about 0.1 to 5.0mm<2> and the ratio of the length/effective sectional area thereof at about 3 to 400mm/mm<2> . The small-diameter part A for flow velocity adjustment is formable of a hollow tube adapted to this size range.  The bag-back filtration of, for example, a low-viscosity white cell-contg. liquid having a viscosity of about <=5.5mPa.s is executable at a fall of about 5 to 2.0m without clogging, etc., by this constitution.
Clinical studies of desmopressin acetate nasal solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience had not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy. 

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Desmopressin acetate nasal solution is contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min). (See CLINICAL PHARMACOLOGY:, Human Pharmacokinetics and CONTRAINDICATION:.)

Use of Desmopressin acetate nasal solution in geriatric patients will require careful fluid intake restriction to prevent possible hyponatremia and water intoxication. (See WARNINGS:). 

There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide.
The system for measuring the radioactive concentration of a radiopharmaceutical includes a container, an interrogation region, a radiation detector, a signal capture device and microprocessor system. The interrogation region associated with the container. The radiation detector to focus detecting radiation emitted from the interrogation region. The signal capture device capable of obtaining a radiation measurement of the interrogation region. The microprocessor system in data communication with the signal capture device. The microprocessor system is capable of calculating a radioactive concentration of a radiopharmaceutical emitting radiation contained in the interrogation region from the signal capture device.
Drug delivery to the cancer cells during its treatment is challenging. Most of the cancer drug cannot reach to the target because of its complex membrane physiology, drug resistance, and mutability. Establishment of a potential target molecule or domain on the cancer cell is the rate limiting step for the successful drug delivery. Cancer is characterized by abnormal energy metabolism shaped by nutrient deprivation that malignant cells experience during various stages of tumor development. This patent demonstrated a new method of establishing a new target domain that could have enormous importance for the drug delivery during cancer treatment. The inventors showed how nutrient-deprived cancer cells become involved in robust membrane glycan display while treating with nucleotide sugar such as sialic acid and that glycosylated membrane domain become a target domain of cancer cell treatment. The inventor showed how to use the lectin, by making a compound with nanomagnetic particles in the treatment of cancer cells. Using the nanomagnetic lectin inventor established an innovative method to treat the cancer cells and showed how prostate cancer cells in the xenograft can be regressed using the technology in the non-limited Example-1 section. In conclusion, nucleotide sugar supplement to nutrient deprived cancer cells enforce them to robust membrane glycan display which could be a novel tool for the successful drug delivery during cancer cell treatment.
Cervical cancer can be eliminated, and the global community intends to achieve this goal in the next century. For this to successfully occur, concerted efforts to implement and scale-up available, evidence-based strategies including human papillomavirus vaccination, screening and treatment of precancerous lesions, and early detection and treatment for invasive cancers is paramount. While the World Health Organization has offered technical guidance and recommendations on implementation, several questions remain unanswered and require urgent high-quality research to inform policy and practice. We discuss the findings from the Cervical Cancer Screening and Treatment Algorithms pilot study in the context of the evidence synthesis conducted for the second edition of the World Health Organization guidelines for screening and treatment of cervical precancer lesions for cervical cancer prevention. Policymakers at the national level must consider the weight of evidence with country-level resources to make decisions on screening, triage, and treatment approaches. See related article by Sebitloane et al., p. 779.
The prescriptive strategy will continue among participants who responded to this intervention well initially, meaning that participants who lost greater than or equal to 2.5 percent (%) of their body weight using the prescriptive intervention. Participants will continue their diet and exercise programs that were initially tailored to them.
The patient education program consists of three individual sessions (consultations with the participant's doctor, one to one and a half hour duration each) and one group session (three hours in groups of up to 16 participants). The program focuses on providing patients with a positive and evidence-based understanding of their illness by providing an individualized bio-psycho-social explanation of multisystem functional somatic disorder.
1. Symptomatic response to therapy with ranitidine hydrochloride does not preclude the presence of gastric malignancy.
  2. Since ranitidine hydrochloride is excreted primarily by the kidney, dosage should be adjusted in patients with impaired renal function (see DOSAGE AND ADMINISTRATION). Caution should be observed in patients with hepatic dysfunction since ranitidine hydrochloride is metabolized in the liver.
  3. In controlled studies in normal volunteers, elevations in SGPT have been observed when H2-antagonists have been administered intravenously at greater-than-recommended dosages for 5 days or longer. Therefore, it seems prudent in patients receiving intravenous ranitidine at dosages ≥100 mg 4 times daily for periods of 5 days or longer to monitor SGPT daily (from day 5) for the remainder of intravenous therapy.
  4. Bradycardia in association with rapid administration of ranitidine injection has been reported rarely, usually in patients with factors predisposing to cardiac rhythm disturbances. Recommended rates of administration should not be exceeded (see DOSAGE AND ADMINISTRATION).
  5. Rare reports suggest that ranitidine hydrochloride may precipitate acute porphyric attacks in patients with acute porphyria. Ranitidine hydrochloride should therefore be avoided in patients with a history of acute porphyria.
BACKGROUND: Eye-related symptoms are a common presentation in the emergency department (ED). The cases range from simple viral conjunctivitis to trauma-related eye injuries. One pathological condition that could lead to vision loss is retinal artery occlusion (RAO). Evaluating a patient with an eye symptom requires thorough eye examination and advanced imaging in certain instances. Consultation with an ophthalmologist is also necessary for cases that require treatment recommendations and further testing. In the ED, point-of-care ultrasound (POCUS) is a commonly used diagnostic tool that can be used for ocular examination.
CASE REPORT: We reported a case of a 60-year-old man who presented with painless partial right-eye vision loss. POCUS showed decreased flow in the right central retinal artery with an area of the pale retina seen on the image from the retinal camera, suggesting a possible branch RAO. Further examination with POCUS showed plaque formation at the carotid bifurcation, a potential cause of the patient's symptoms. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Emergency physicians and other providers should be encouraged to use POCUS to diagnose eye symptoms accurately and promptly. Abnormal findings will prompt immediate specialty consult and early appropriate management. Our case and other reported cases highlight POCUS's reliability and rapid diagnostic ability.
The present invention relates to a novel cell endocytic regulatory protein(Rab39). The present invention provides polynucleotide for coding the molecule of the protein and a method for producing the protein by recombination technology. The present invention also discloses the applications of the polynucleotide for coding the molecule of the novel cell cycle regulatory protein. The present invention also relates to the functions of the molecule in regulating the protein. The present invention also discloses the diagnosis and therapeutic strategies of diseases by molecules resisting the protein. The present invention can be particularly used for diagnosing and treating inflammation, tumors, diseases of the nervous system, the respiratory system and the endocrine system and cardiovascular diseases.
Background: The vascular endothelial growth factor (VEGF) polymorphism is associated with preeclampsia since its abnormal expression plays an important role in vasculogenesis in placenta formation. Thus, this study is aimed at analyzing the association between VEGF +936C/T polymorphism and the risk of preeclampsia. Methods: To assess the causal relationship, a hospital-based cross-sectional analytical study was carried out among 204 Myanmar pregnant women during the period of January 2018-September 2020. For data collection, a pretested, structured questionnaire was used. Blood samples were collected after obtaining consent, and then we studied the extracted gene by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The Statistical Package for Social Sciences version 18.0 was used for data management and analysis. Results: The genotype CT variant among preeclamptic women was more than that of non-preeclamptic women (26.5% vs. 18.6%), but not significant (p = 0.180). The risk of preeclampsia among women with CT genotypes was 1.57 times higher than that of women with CC genotypes (OR (95%CI) = 1.57 (0.81, 3.06), p = 0.180). The minor allele frequency of the T allele was 15.2% in preeclamptic women and 9.3% in normal pregnant women. The risk of preeclampsia among T allele carriers is 1.49 times (95%CI = 0.80, 2.77) more than that of C allele carriers (p = 0.211). Among the preeclamptic pregnant women, the frequency of the CT genotype was 26.3% in the severe preeclamptic group and 26.9% in the mild preeclamptic group, while the frequency of the T allele was 13.2% and 13.5%, respectively. The frequency of either CT genotype or T allele was more or less the same in both groups, and there was no association between VEGF C/T polymorphism and the severity of preeclampsia. After logistic regression analysis on VEGF genotype and clinical parameters such as age, maternal body mass index (BMI), and neonatal birth weight, the risk of preeclampsia was 2.1 times higher in pregnant women with CT genotype compared to CC genotype (adjusted OR, 2.1; 95% CI, 0.9-4.5, p value -0.057). Conclusion: There was no significant association between VEGF +936C/T polymorphism (rs3025039) and preeclampsia among Myanmar pregnant women. However, the findings of this study highlighted that individuals carrying either the CT genotype or the T allele are at a heightened risk of developing preeclampsia. Furthermore, it suggests a potential impact of the gene on the occurrence of preeclampsia, yet the data lacks sufficient evidence to establish statistical significance.
Participants will first be assigned to receive monthly monitoring of social communication development. At month 3 participants' social communication will be evaluated. Participants who present with delayed social communication skills will be randomly assigned to 2 additional treatment options: continue, or add video feedback. Participants who do not present with social communication delays will continue to receive developmental monitoring.
FIELD: cosmetic industry. SUBSTANCE: washing liquid contains oxyethylated sodiumlaurylsulfate, diethanolamides, sodium chloride, citric acid, dyestuff, flavoring, water. It additionally includes biologically active additive, glycerine, oil extracts of plants, nipagin and nipazol. All components are taken in preset quantitative ratio. The washing liquid gives hair vivid shine and has pleasant odor. EFFECT: improved structure of hair. 1 cl, 3 tbl, 1 ex
Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
INTRODUCTION: The frequency of proximal humeral fractures shows an increasing tendency, especially in the elderly, who are frequently affected by osteoporosis. The adequate treatment of complex, displaced fractures poses a serious challenge. Among surgical treatment options, osteosynthesis with an angular stable plate is preferred, however, the implant-related complication rate may be exceptionally high. In our present study, we report the short-term outcomes of our new method of valgising angular stable plate fixation which we use for multifragmentary, displaced proximal humeral fractures in elderly patients.
MATERIALS AND METHODS: We retrospectively evaluated the clinical and radiological outcomes of 52 patients (46 female and 6 male, age: 71.9 ± 9.6) who suffered dislocated three- or four-part fractures and underwent valgising angular stable plate fixation.
RESULTS: Mean follow-up time was 17.3 months, while the functional outcomes were as following: excellent in 26, good in 18, moderate in 5 and poor in 3 patients. The mean Constant-Murley Score was 82.5 ± 11.2. Functional outcomes only showed significant correlation (p = 0.031) with age and were proven unrelated to fracture type, BMI and known primary diseases. The cumulative complication rate was 9.6% and revision rate was 5.8%. Neurological deficit, pseudoarthrosis or avascular humeral head necrosis did not occur during the follow-up period.
CONCLUSIONS: Valgising angular stable plate fixation that we apply for proximal humeral fractures provided favourable functional outcomes and a low postoperative complication rate due to the optimal head and plate placement. The method is especially effective for the treatment of displaced three- and four-part fractures with weakened, osteoporotic bone structure.
Method for obtaining a pig skin dressing consists of separating epidermis with a layer thickness of 0.5mm to 2.0 mm, preferably 1 mm, from the collected material. Then the material is purified in any physiological liquid, preferably one having isotonic properties with reject to the tissues of warm-blooded animals and humans with osmolality in the range from 295 mOsm/L to 320 mOsm/L, preferably in physiological saline or Fresenius-Kabi fluid, while rolling in order to maintain the shape of the material and maintain constant humidity of the material across the entire volume, after which the material is washed in an ultrasonic bath. The next step is preservation in a solution composed of DMSO and glycerine at a temperature of 1-20°C for a period of time from 1 minute up to 10 minutes, the material being preserved under vacuum sealing in a solution containing DMSO and glycerine in amounts 1-15% v/v DMSO and 85- 99% v/v glycerine, used in an amount of 2-10 ml per 1 cm 2  of the sample. Next, the material is subjected to a stepwise lowering of temperature: initially it is cooled for 10-30 min at VC to - 20°C, then it is subjected to freezing first at -10°C to -25°C for 4-8 hours, then at -50°C to - 85°C, preferably -75°C for 30-60 hours. The material prepared in this way is incubated in liquid nitrogen vapor for 30-60 hours, and then left in liquid nitrogen for 30-60 hours. Then tile material is thawed for 1-8 hours, rinsed in buffered washing liquids with simultaneous rolling and washed in an ultrasonic bath. The material prepared in this way is lyophilized, after which it is dosed in an airtight container under inert gas atmosphere and subjected to radiation sterilization.
The human respiratory system is susceptible to a variety of diseases, ranging from chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis to acute respiratory distress syndrome (ARDS). Today, lung diseases represent one of the major challenges to the health care sector and represent one of the leading causes of death worldwide. Current treatment options often focus on managing symptoms rather than addressing the underlying cause of the disease. The limitations of conventional therapies highlight the urgent clinical need for innovative solutions capable of repairing damaged lung tissue at a fundamental level. Pluripotent stem cell technologies have now reached clinical maturity and hold immense potential to revolutionize the landscape of lung repair and regenerative medicine. Meanwhile, human embryonic (HESCs) and human-induced pluripotent stem cells (hiPSCs) can be coaxed to differentiate into lung-specific cell types such as bronchial and alveolar epithelial cells, or pulmonary endothelial cells. This holds the promise of regenerating damaged lung tissue and restoring normal respiratory function. While methods for targeted genetic engineering of hPSCs and lung cell differentiation have substantially advanced, the required GMP-grade clinical-scale production technologies as well as the development of suitable preclinical animal models and cell application strategies are less advanced. This review provides an overview of current perspectives on PSC-based therapies for lung repair, explores key advances, and envisions future directions in this dynamic field.
Infectious esophagitis (IE) is the leading cause of esophagitis, second only to gastroesophageal reflux disease. Infectious esophagitis is typically observed in immunocompromised individuals due to neutropenia, HIV/AIDS, solid organ malignancies, cancer-directed therapy, or chronic steroid use. The most common causes of IE are herpes simplex virus (HSV), cytomegalovirus (CMV), and Candida albicans. Acute bacterial esophagitis is exceedingly rare, particularly in immunocompetent patients. Herein, we describe a unique case of acute streptococcal esophagitis in a male patient with no pertinent medical history. The patient's substernal chest pain and odynophagia resolved after antibiotic treatment.